Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2006

View Archived Issues

De Novo enters drug discovery collaboration with Genzyme

Potent and selective AEA reuptake inhibitors as antispastics in MS

A.P. Pharma sells royalty rights to Retin-A Micro and Carac

New investment supports GammaCan's phase II study of GCAN-101

BioVeris signs option agreement with TheraCarb for C. albicans vaccine candidate

Merck Frosst presents a new potent, selective orally active cathepsin K inhibitor

Phase I study completed for KB-2115

Department of Defense grant for preclinical study of Tarvacin for prostate cancer

Positive phase III results for SPP-100 in hypertension

Shareholders vote in favor of Crucell's offer for Berna

NanoCarrier to conduct phase I study of Nanoplatin in U.K.

Tolamba shows clinical benefit in reducing symptoms of ragweed allergy

GdSSR: A novel putative approach for glioblastoma multiforme treatment

NovImmune files IND for antibody for autoimmune disease

EDP-420 begins North American phase II trial for CAP

Enrollment nearing completion in phase IIIb mesothelioma study of Onconase

Phase III development of Acapodene recommended to continue

Panzem studied in phase II for recurring GBM

Arteriocyte studies adult derived hemangioblasts to treat chronic ischemia

Procyon Biopharma and Cellpep to merge to form Ambrilia Biopharma

HPV-specific inhibitors from Boehringer Ingelheim as a gateway for future drug design

Novel agents imparted for inflammatory disorders

Taisho patent describes compounds with potential for the treatment for renal disorders, etc.

Recent patents cover novel treatments for psychological disorders

Neuroprotective effects of targeting IKK for stroke

New therapeutics for cancer covered in recent patent literature

SuperGen withdraws Orathecin MAA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...